Zobrazeno 1 - 10
of 581
pro vyhledávání: '"Leo A. Gordon"'
Autor:
Megan Melody, Leo I. Gordon
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Historically, management of relapsed or refractory (R/R) Diffuse large B-cell (DLBCL) following first-line chemoimmunotherapy has been second-line chemotherapy, followed by high-dose chemotherapy and consolidative autologous hematopoietic stem cell t
Externí odkaz:
https://doaj.org/article/4e0c311965b74081bff0bceebd73e913
Autor:
Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-7 (2023)
Abstract Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performe
Externí odkaz:
https://doaj.org/article/c3e2fa17ee934883ab1d81fbb67a6b3b
Autor:
Reem Karmali, Frederique St‐Pierre, Shuo Ma, Kelly D. Foster, Jason Kaplan, Xinlei Mi, Barbara Pro, Jane N. Winter, Leo I. Gordon
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 108-114 (2023)
Abstract Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I single‐institution escalation study of front‐line treatment with R
Externí odkaz:
https://doaj.org/article/4ddec0d795ad48768f1172140048cc49
Autor:
Leo I. Gordon, Fei Fei Liu, Julia Braverman, Daanish Hoda, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, Lily Peng, Shien Guo, Ling Shi, Alison Sehgal
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
In the single-arm, open-label, multicenter, phase II PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (L
Externí odkaz:
https://doaj.org/article/f85d926987c6464784c910fa8b1e7fda
Autor:
Adam Yuh Lin, Leo I. Gordon
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 13 (2023)
The study of the cellular and molecular microenvironment in B cell lymphoma, especially diffuse large B cell lymphoma (DLBCL), has led to prognostic and therapeutic algorithms that may improve patient outcomes. Emerging gene signature panels provide
Externí odkaz:
https://doaj.org/article/0f96eed0eb5346f7abaa824e3400ef68
Publikováno v:
eJHaem, Vol 1, Iss 2, Pp 596-600 (2020)
Abstract Ibrutinib, a known Burton's tyrosine kinase (BTK) and interleukin‐2 inducible T‐cell kinase (ITK) inhibitor, is used for the treatment of B‐cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic gra
Externí odkaz:
https://doaj.org/article/464fc94fbbfd4931a8a7970c5c291347
Autor:
Alain Mina, Carlos Galvez, Reem Karmali, Mary Mulcahy, Xinlei Mi, Masha Kocherginsky, Michael J Gurley, Neelima Katam, William Gradishar, Jessica K Altman, Michael G Ison, Dean Tsarwhas, Christopher George, Jane N Winter, Leo I. Gordon, Firas H Wehbe, Leonidas C Platanias
Publikováno v:
Cancers, Vol 14, Iss 9, p 2209 (2022)
Patients with a history of malignancy have been shown to be at an increased risk of COVID-19-related morbidity and mortality. Poorer clinical outcomes in that patient population are likely due to the underlying systemic illness, comorbidities, and th
Externí odkaz:
https://doaj.org/article/d9b453b5fe7f4f12a399f363fae6ea41
Autor:
Brendan E. Hawkins, Theresa Schoetz, Leo W. Gordon, Surabh KT, Jonah Wang, Robert J. Messinger
Publikováno v:
The Journal of Physical Chemistry Letters. 14:2378-2386
Autor:
Frédérique St-Pierre, Leo I Gordon
Publikováno v:
Future Oncology. 19:19-28
Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval o
Autor:
Reem Karmali, Frederique St‐Pierre, Shuo Ma, Kelly D. Foster, Jason Kaplan, Xinlei Mi, Barbara Pro, Jane N. Winter, Leo I. Gordon
Publikováno v:
eJHaem. 4:108-114